NasdaqGS - Nasdaq Real Time Price ? USD Crinetics Pharmaceuticals, Inc. (CRNX) Follow Compare 59.09 +0.17 (+0.29%) At close: October 18 at 4:00 PM EDT 59.95 +0.86 (+1.46%) After hours: October 18 at 5:18 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals On September 30, 2024, State Street Corp made a significant addition to its investment portfolio by acquiring 2,838,484 shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX). This transaction, executed at a price of $51.10 per share, marks a notable expansion in State Street Corp's holdings within the biotechnology sector. The addition of these shares has increased the firm's total stake in Crinetics Pharmaceuticals to a substantial 3.60% of its portfolio, reflecting a strategic move to bolster its presence in the biotech industry. GuruFocus.com ? 3 days ago CRNX +0.29% STT Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Tuesday, November 12 @ 4:30 p.m. ET Domestic: 1-800-579-2543International: 1-785-424-1789Conference ID: CRNXQ3 Participants can use GlobeNewswire ? 4 days ago CRNX +0.29% Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 258,800 shares of its common stock to twenty-seven new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as ind GlobeNewswire ? 10 days ago CRNX +0.29% Morning Movers: Arcadium Lithium surges after deal to be acquired Check out this morning’s top movers from around Wall Street, compiled by The Fly. HIGHER – Arcadium Lithium (ALTM) up 30% after Rio Tinto (RIO) and the company announced a definitive agreement under which Rio Tinto will acquire Arcadium in an all-cash transaction for $5.85 per share Clearside Biomedical (CLSD) up 10% after announcing that the ODYSSEY Phase 2b clinical trial of CLS-AX, or axitinib injectable suspension, for the treatment of neovascular age-related macular degeneration achieved bo TipRanks ? 10 days ago ALTM ARLTF BA Crinetics Pharmaceuticals Inc (CRNX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... Despite increased losses and expenses, Crinetics Pharmaceuticals Inc (CRNX) showcases promising clinical progress and a robust financial position to support future growth. GuruFocus.com ? 11 days ago CRNX +0.29% Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an upsized underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $50.00 per share. All of the shares to be sold in the offering are to be sold by Crinetics. GlobeNewswire ? 11 days ago CRNX +0.29% Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, $400.0 million of shares of its common stock in a proposed underwritten public offering. In addition, Crinetics intends to grant the underwri GlobeNewswire ? 12 days ago CRNX +0.29% Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist in development for the proposed treatment and long-term maintenance therapy of acromegaly. “This NDA submission brings us one step closer to our goal of delivering a new generation of GlobeNewswire ? 24 days ago CRNX +0.29% Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ... Crinetics Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Over the past year, Stephen Betz has sold a total of 40,035 shares of the company and has not made any purchases. The insider transaction history for Crinetics Pharmaceuticals Inc shows a trend with 37 insider sells and no insider buys over the past year. GuruFocus.com ? last month CRNX +0.29% Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 120,200 shares of its common stock to fifteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as induc GlobeNewswire ? last month CRNX +0.29% Crinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy Now We recently compiled a list of the 10 Best Mid-Cap Healthcare Stocks To Buy Now. In this article, we are going to take a look at where Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands against the other mid-cap healthcare stocks. Global Healthcare Market: Growth Projections, Challenges, and Tech-Driven Innovations According to projections by ReportLinker, the market for healthcare […] Insider Monkey ? last month CRNX +0.29% Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that company management will participate in fireside chats at the Morgan Stanley 22nd Annual Global Healthcare Conference and the Cantor Global Healthcare Conference both being held in New York, NY in September. Morg GlobeNewswire ? last month CRNX +0.29% Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ... The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 69,611 shares of Crinetics Pharmaceuticals Inc. Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. GuruFocus.com ? last month CRNX +0.29% Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 103,900 shares of its common stock to fifteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducemen GlobeNewswire ? 2 months ago CRNX +0.29% We Think Crinetics Pharmaceuticals (NASDAQ:CRNX) Can Afford To Drive Business Growth We can readily understand why investors are attracted to unprofitable companies. By way of example, Crinetics... Simply Wall St. ? 2 months ago CRNX +0.29% Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -9.30% and 70.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 2 months ago CRNX +0.29% Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results?and Provides Business Update Paltusotine NDA Submission in Acromegaly On Track for 2024 Topline Results from Phase 2 Studies of Atumelnant in Congenital Adrenal Hyperplasia and Additional Data for Phase 2 for ACTH-Dependent Cushing’s Syndrome Expected by End of 2024 Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel the GlobeNewswire ? 2 months ago CRNX +0.29% Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges ACRO/TRUTH Provides Authentic Patient Perspectives, Peer-Reviewed Data on Treatment-Related Symptoms, Side Effects and Quality-of-Life Impact of Current Acromegaly Standard-of-CareSAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the launch of the ACRO/TRUTH healthcare provider (HCP) educational website and initiative, the purpose of which is to spotlight the significant challenges and burdens many people living with acromegaly experience GlobeNewswire ? 2 months ago CRNX +0.29% Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline Zevra Therapeutics (ZVRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Zacks ? 2 months ago ZVRA CRNX +0.29% Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Crinetics Pharmaceuticals (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Zacks ? 2 months ago CRNX +0.29% PTCT Performance Overview Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return CRNX S&P 500 YTD +66.08% +22.95% 1-Year +105.96% +34.10% 3-Year +203.18% +31.16%
